Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) closed its acquisition of Corstasis Therapeutics on April 2, 2026, adding Enbumyst, the first and only FDA‑approved nasal spray loop diuretic. Enbumyst received FDA approval in September 2025 for edema associated with congestive heart failure, hepatic, and renal disease.
The acquisition expands Esperion’s cardiovascular franchise into outpatient, acute‑adjacent care and aims to leverage existing commercial infrastructure to accelerate adoption, payer engagement, and patient access.
Esperion (NASDAQ: ESPR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 9:30 a.m. ET, with a live webcast available on the company investor site. A replay will be posted about two hours after the call and archived for ~90 days.
Esperion is a commercial-stage cardiometabolic biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with approvals in more than 40 countries and an R&D pipeline targeting ACLY biology, Primary Sclerosing Cholangitis, and renal diseases.
Esperion (NASDAQ: ESPR) presented two post-hoc CLEAR Outcomes analyses at ACC.26 (Mar 28-30, 2026) showing clinical benefits of bempedoic acid (NEXLETOL/NEXLIZET). Key findings: a 22% reduced risk of ischemic stroke in statin-intolerant patients and similar MACE risk reduction in patients with autoimmune or inflammatory diseases.
The company highlighted safety considerations including hyperuricemia, gout risk, and a small increased tendon rupture incidence observed in trials.
Esperion (NASDAQ: ESPR) announced two moderated poster presentations from the CLEAR Outcomes trial at the American College of Cardiology 2026 Annual Scientific Session (ACC.26), March 28-30 in New Orleans.
Both analyses evaluate bempedoic acid in underrepresented populations: stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases.
Esperion (NASDAQ: ESPR) announced that bempedoic acid earned multiple Class 1 recommendations in the 2026 ACC/AHA multisociety dyslipidemia guideline (published March 16, 2026), including for patients with statin intolerance, severe hypercholesterolemia, and selected primary and secondary prevention groups.
The guideline places bempedoic acid alongside ezetimibe and PCSK9 mAb after statins, reintroduces LDL-C targets, and supports earlier combination oral therapy to reduce ASCVD risk.
Esperion (NASDAQ: ESPR) reported FY2025 total revenue of $403.1M (21% Y/Y) and Q4 revenue of $168.4M (144% Y/Y). U.S. net product revenue grew ~38% Y/Y to $159.6M for FY2025. The company announced an agreement to acquire Corstasis and Enbumyst™, and strengthened patent settlements and payer coverage.
Key financials: Q4 U.S. product sales $43.7M, collaboration revenue driven by a $90M Otsuka payment, FY net loss $22.7M, cash $167.9M, and 2026 operating expense guidance of $225M–$255M.
Esperion (NASDAQ: ESPR) agreed to acquire Corstasis to add Enbumyst™ (bumetanide nasal spray), the first FDA‑approved intranasal loop diuretic (approved Sept 2025), for edema associated with CHF, hepatic and renal disease. The deal includes a $75 million upfront cash payment, up to $180 million in milestones, low double‑digit royalties, and expected close in Q2 2026.
Esperion will finance the transaction via existing credit facilities and royalty monetization and expects the product to leverage its cardiovascular commercial infrastructure to drive double‑digit revenue growth and expand its portfolio.
Esperion (NASDAQ: ESPR) will report Q4 and full-year 2025 financial results before the market opens on Tuesday, March 10, 2026. Management will host a live audio webcast at 8:00 a.m. ET to discuss results and business updates.
Webcast access and a replay will be available on the company's investor site, with the replay archived for approximately 90 days.
Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET. The presentation will be webcast live and accessible via the company’s investor and media website. A replay will be available about two hours after the call and archived for approximately 90 days.
Esperion (NASDAQ: ESPR) announced a settlement with Alkem Laboratories resolving patent litigation over NEXLETOL and NEXLIZET. Under the agreement, Alkem agreed not to market generic versions in the U.S. prior to April 19, 2040, subject to customary limited exceptions.
Litigation against four other ANDA filers remains pending, and there is no assurance those cases will prevent earlier generic entry.